Nifty
Sensex
:
:
25800.60
83919.71
286.30 (1.12%)
897.96 (1.08%)

Pharmaceuticals & Drugs - Global

Rating :
49/99

BSE: 500124 | NSE: DRREDDY

1390.20
20-Nov-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1388
  •  1400
  •  1384.8
  •  1400.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  830660
  •  1156504970.4
  •  1414.9
  •  1101

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,16,144.51
  • 41.48
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,18,377.91
  • 0.58%
  • 2.99

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.63%
  • 0.42%
  • 7.53%
  • FII
  • DII
  • Others
  • 20.3%
  • 28.73%
  • 16.39%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.03
  • 9.36
  • 6.36

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.07
  • 11.37
  • -4.04

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.81
  • 13.97
  • -9.05

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.79
  • 19.97
  • 19.20

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.63
  • 3.39
  • 3.22

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.26
  • 12.97
  • 12.36

Earnings Forecasts:

(Updated: 14-11-2026)
Description
2026
2027
2028
2029
Adj EPS
51.48
43.44
59.16
70.1
P/E Ratio
27.00
32.00
23.50
19.83
Revenue
33593.3
35117.1
39330.3
44388
EBITDA
7115.6
6315.19
8091.42
9367.45
Net Income
4285
3647.63
4919.52
5868.71
ROA
7.99
6
7.84
7.98
P/B Ratio
3.07
2.85
2.59
2.34
ROE
12.06
9.19
11.32
12.22
FCFF
3050.9
3818.27
3282.3
4234.6
FCFF Yield
2.65
3.32
2.85
3.68
Net Debt
-1047.3
-3884.04
-5801.55
-7710.48
BVPS
452.82
487.94
537.69
594.36

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 26
Sep 25
Var%
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Net Sales
8,697.80
8,828.30
-1.48%
8,099.80
8,572.10
-5.51%
7,546.40
8,528.40
-11.51%
8,753.40
8,381.20
4.44%
Expenses
6,967.20
6,818.40
2.18%
7,239.90
6,398.50
13.15%
7,163.90
6,530.50
9.70%
6,865.90
6,108.20
12.40%
EBITDA
1,730.60
2,009.90
-13.90%
859.90
2,173.60
-60.44%
382.50
1,997.90
-80.85%
1,887.50
2,273.00
-16.96%
EBIDTM
19.90%
22.77%
10.62%
25.36%
5.07%
23.43%
21.56%
27.12%
Other Income
156.20
323.90
-51.78%
354.70
290.30
22.18%
475.40
522.10
-8.94%
268.80
150.20
78.96%
Interest
124.80
90.70
37.60%
125.50
83.00
51.20%
105.70
65.60
61.13%
94.40
81.70
15.54%
Depreciation
526.70
504.60
4.38%
536.60
476.10
12.71%
557.10
454.70
22.52%
521.00
471.40
10.52%
PBT
1,235.30
1,738.50
-28.94%
552.50
1,904.80
-70.99%
195.10
1,999.70
-90.24%
1,540.90
1,870.10
-17.60%
Tax
314.40
408.00
-22.94%
117.70
495.10
-76.23%
-21.60
418.50
-
353.60
470.10
-24.78%
PAT
920.90
1,330.50
-30.79%
434.80
1,409.70
-69.16%
216.70
1,581.20
-86.30%
1,187.30
1,400.00
-15.19%
PATM
10.59%
15.07%
5.37%
16.45%
2.87%
18.54%
13.56%
16.70%
EPS
11.08
16.13
-31.31%
5.32
16.98
-68.67%
2.65
19.10
-86.13%
14.49
16.95
-14.51%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Net Sales
33,097.40
33,700.20
32,643.90
28,011.10
24,669.70
21,545.20
19,047.50
17,517.00
15,448.20
14,281.00
14,196.10
Net Sales Growth
-3.53%
3.24%
16.54%
13.54%
14.50%
13.11%
8.74%
13.39%
8.17%
0.60%
 
Cost Of Goods Sold
12,861.20
12,239.20
9,979.90
8,208.70
7,657.70
7,442.20
6,078.90
5,554.40
4,494.80
4,039.50
3,696.50
Gross Profit
20,236.20
21,461.00
22,664.00
19,802.40
17,012.00
14,103.00
12,968.60
11,962.60
10,953.40
10,241.50
10,499.60
GP Margin
61.14%
63.68%
69.43%
70.69%
68.96%
65.46%
68.09%
68.29%
70.90%
71.71%
73.96%
Total Expenditure
28,236.90
27,246.70
24,096.80
20,078.00
18,320.70
17,777.80
15,177.60
15,046.60
12,270.00
11,929.80
11,723.90
Power & Fuel Cost
-
556.50
562.50
533.90
477.40
390.50
320.50
314.80
329.10
329.30
330.10
% Of Sales
-
1.65%
1.72%
1.91%
1.94%
1.81%
1.68%
1.80%
2.13%
2.31%
2.33%
Employee Cost
-
5,990.90
5,580.00
5,030.10
4,646.60
3,885.80
3,629.90
3,380.20
3,356.20
3,214.90
3,106.80
% Of Sales
-
17.78%
17.09%
17.96%
18.84%
18.04%
19.06%
19.30%
21.73%
22.51%
21.88%
Manufacturing Exp.
-
2,242.70
2,563.20
2,087.20
1,738.60
1,602.20
1,574.40
1,445.40
1,434.80
1,746.50
1,886.60
% Of Sales
-
6.65%
7.85%
7.45%
7.05%
7.44%
8.27%
8.25%
9.29%
12.23%
13.29%
General & Admin Exp.
-
2,084.40
2,173.20
1,848.20
1,497.50
1,547.60
1,251.80
1,195.20
1,132.10
1,193.40
1,339.90
% Of Sales
-
6.19%
6.66%
6.60%
6.07%
7.18%
6.57%
6.82%
7.33%
8.36%
9.44%
Selling & Distn. Exp.
-
3,597.50
2,925.50
2,248.20
1,989.40
1,919.20
1,567.70
1,408.30
1,423.50
1,330.20
1,293.40
% Of Sales
-
10.68%
8.96%
8.03%
8.06%
8.91%
8.23%
8.04%
9.21%
9.31%
9.11%
Miscellaneous Exp.
-
535.50
312.50
121.70
313.50
990.30
754.40
1,748.30
99.50
76.00
1,293.40
% Of Sales
-
1.59%
0.96%
0.43%
1.27%
4.60%
3.96%
9.98%
0.64%
0.53%
0.50%
EBITDA
4,860.50
6,453.50
8,547.10
7,933.10
6,349.00
3,767.40
3,869.90
2,470.40
3,178.20
2,351.20
2,472.20
EBITDA Margin
14.69%
19.15%
26.18%
28.32%
25.74%
17.49%
20.32%
14.10%
20.57%
16.46%
17.41%
Other Income
1,255.10
1,358.40
1,097.30
894.30
1,055.50
484.70
291.40
620.60
337.50
155.20
171.50
Interest
450.40
373.80
282.90
171.10
142.80
95.80
97.00
98.30
88.90
78.80
63.40
Depreciation
2,141.40
2,058.80
1,703.70
1,470.00
1,250.20
1,165.20
1,228.80
1,163.10
1,134.80
1,077.20
1,026.60
PBT
3,523.80
5,379.30
7,657.80
7,186.30
6,011.50
2,991.10
2,835.50
1,829.60
2,292.00
1,350.40
1,553.70
Tax
764.10
1,235.10
1,954.30
1,623.10
1,541.20
878.90
931.90
-140.30
385.80
438.00
296.50
Tax Rate
21.68%
22.96%
25.52%
22.59%
25.64%
29.38%
32.87%
-7.67%
16.83%
32.43%
19.08%
PAT
2,759.70
4,196.00
5,655.10
5,577.90
4,507.30
2,182.50
1,951.60
2,026.00
1,950.00
912.40
1,257.20
PAT before Minority Interest
2,799.90
4,157.60
5,725.20
5,577.90
4,507.30
2,182.50
1,951.60
2,026.00
1,950.00
912.40
1,257.20
Minority Interest
40.20
38.40
-70.10
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
8.34%
12.45%
17.32%
19.91%
18.27%
10.13%
10.25%
11.57%
12.62%
6.39%
8.86%
PAT Growth
-51.77%
-25.80%
1.38%
23.75%
106.52%
11.83%
-3.67%
3.90%
113.72%
-27.43%
 
EPS
37.19
56.54
76.20
75.16
60.74
29.41
26.30
27.30
26.28
12.29
16.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Shareholder's Funds
37,891.50
33,549.60
28,254.80
23,286.10
19,212.40
17,641.70
15,598.80
14,023.60
12,571.60
12,262.10
Share Capital
83.50
83.40
83.40
83.30
83.20
83.20
83.10
83.00
83.00
82.90
Total Reserves
37,659.10
33,321.50
28,040.10
23,057.10
18,985.90
17,431.90
15,411.90
13,861.10
12,406.00
12,098.80
Non-Current Liabilities
926.10
632.90
-36.80
-278.30
-508.30
-197.30
-807.50
2,113.00
2,538.40
456.10
Secured Loans
1,220.30
406.40
219.00
127.80
194.60
249.90
130.40
55.20
63.00
59.70
Unsecured Loans
0.00
380.00
380.00
0.00
380.00
380.00
0.00
2,144.80
2,445.90
485.20
Long Term Provisions
33.80
29.80
23.90
19.90
25.80
50.80
74.50
79.30
81.70
84.20
Current Liabilities
16,747.40
13,033.80
9,588.00
8,572.10
9,765.80
8,103.80
7,214.10
5,897.30
6,893.80
8,419.90
Trade Payables
3,037.90
2,647.80
2,614.40
2,268.40
2,266.20
1,810.90
1,524.80
1,367.10
1,334.50
1,056.90
Other Current Liabilities
6,490.60
5,503.10
4,775.20
4,697.90
3,660.60
3,338.10
3,512.00
2,820.70
2,411.40
2,339.70
Short Term Borrowings
5,913.60
3,804.50
1,272.30
739.00
2,708.20
2,314.50
1,653.20
1,212.50
2,556.20
4,362.60
Short Term Provisions
1,305.30
1,078.40
926.10
866.80
1,130.80
640.30
524.10
497.00
591.70
660.70
Total Liabilities
55,904.40
47,594.10
37,806.00
31,579.90
28,469.90
25,548.20
22,005.40
22,033.90
22,003.80
21,138.10
Net Block
22,063.30
18,226.40
10,425.60
9,219.10
8,121.50
8,205.70
6,850.30
7,191.00
6,968.00
6,930.70
Gross Block
43,854.30
36,759.60
24,527.40
25,567.10
23,096.40
21,886.70
19,335.50
18,048.40
17,436.30
15,932.40
Accumulated Depreciation
21,494.10
18,533.20
14,101.30
16,348.00
14,894.90
13,632.10
12,485.20
10,857.40
10,468.30
9,001.70
Non Current Assets
25,875.60
22,576.10
13,000.70
11,154.50
10,682.00
10,997.90
9,406.30
10,923.80
11,505.40
11,454.40
Capital Work in Progress
1,460.20
2,465.60
1,419.30
1,030.10
1,293.40
1,565.10
1,535.10
2,933.50
3,470.50
3,324.50
Non Current Investment
1,612.00
720.50
525.50
536.30
593.00
833.30
309.10
334.20
465.30
682.60
Long Term Loans & Adv.
506.60
341.40
541.80
355.90
451.70
377.00
688.70
426.70
564.80
482.10
Other Non Current Assets
233.50
822.20
88.50
13.10
222.40
16.80
23.10
38.40
36.80
34.50
Current Assets
30,028.80
25,018.00
24,805.30
20,425.40
17,787.90
14,535.20
12,599.10
11,110.10
10,498.40
9,683.70
Current Investments
3,672.80
3,330.60
4,405.00
4,449.50
2,022.90
1,378.50
2,368.70
2,252.90
1,833.00
1,427.10
Inventories
7,653.40
7,108.50
6,355.20
4,867.00
5,088.40
4,541.20
3,506.70
3,357.90
2,908.90
2,852.80
Sundry Debtors
10,123.40
9,042.00
8,029.80
7,248.50
6,676.40
4,964.10
5,027.80
3,986.90
4,052.70
3,798.60
Cash & Bank
3,348.70
2,460.20
1,727.70
1,730.20
2,419.20
2,078.80
205.30
222.80
263.80
386.50
Other Current Assets
5,230.50
1,072.40
1,011.30
1,203.50
1,581.00
1,572.60
1,490.60
1,289.60
1,440.00
1,218.70
Short Term Loans & Adv.
4,047.10
2,004.30
3,276.30
926.70
844.10
722.70
444.50
439.80
674.10
767.20
Net Current Assets
13,281.40
11,984.20
15,217.30
11,853.30
8,022.10
6,431.40
5,385.00
5,212.80
3,604.60
1,263.80
Total Assets
55,904.40
47,594.10
37,806.00
31,579.90
28,469.90
25,533.10
22,005.40
22,033.90
22,003.80
21,138.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Cash From Operating Activity
5,673.70
4,642.80
4,543.30
5,887.50
2,810.80
3,570.30
2,984.10
2,870.40
1,803.00
2,144.40
PBT
5,392.70
7,679.50
7,201.00
6,048.50
3,061.40
2,883.50
1,885.70
2,335.80
1,350.40
1,553.70
Adjustment
2,708.20
1,961.50
1,365.20
1,695.90
2,333.80
2,087.20
2,562.50
835.00
1,625.30
1,687.30
Changes in Working Capital
-1,074.60
-2,998.90
-2,018.20
-785.50
-1,840.70
-828.80
-753.60
183.70
-896.60
-519.60
Cash after chg. in Working capital
7,026.30
6,642.10
6,548.00
6,958.90
3,554.50
4,141.90
3,694.60
3,354.50
2,079.10
2,721.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,352.60
-1,999.30
-2,004.70
-1,071.40
-743.70
-571.60
-710.50
-484.10
-276.10
-577.00
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-6,549.30
-5,807.70
-4,028.30
-4,137.30
-2,638.70
-2,266.00
-492.30
-772.70
-1,488.30
-1,840.40
Net Fixed Assets
-2,801.90
-2,403.40
-1,447.20
-1,511.60
-1,303.60
-2,618.10
-453.50
-275.60
-683.20
-1,019.30
Net Investments
-2,401.30
-5,872.90
119.40
-2,503.30
-287.50
836.30
-1,552.00
-297.00
-534.60
1,974.20
Others
-1,346.10
2,468.60
-2,700.50
-122.40
-1,047.60
-484.20
1,513.20
-200.10
-270.50
-2,795.30
Cash from Financing Activity
829.00
1,891.10
-376.30
-2,686.10
-242.20
-29.80
-2,515.90
-2,132.60
-444.00
-369.20
Net Cash Inflow / Outflow
-46.60
726.20
138.70
-935.90
-70.10
1,274.50
-24.10
-34.90
-129.30
-65.20
Opening Cash & Equivalents
1,459.30
710.70
577.90
1,485.20
1,482.00
196.20
222.80
254.20
377.80
492.10
Closing Cash & Equivalent
1,536.80
1,459.30
710.70
577.90
1,485.20
1,482.00
196.20
222.80
254.20
377.80

Financial Ratios

Consolidated /

Standalone
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Book Value (Rs.)
452.01
400.54
337.21
277.80
1145.98
1052.59
932.31
840.01
752.35
734.72
ROA
8.03%
13.41%
16.08%
15.01%
8.08%
8.01%
8.95%
8.66%
4.23%
6.14%
ROE
11.69%
18.61%
21.76%
21.36%
11.93%
11.53%
13.38%
14.42%
7.40%
10.20%
ROCE
13.75%
23.25%
26.86%
26.22%
14.59%
15.24%
10.81%
13.41%
8.21%
9.77%
Fixed Asset Turnover
0.84
1.07
1.12
1.01
0.96
0.92
0.94
0.87
0.86
0.92
Receivable days
103.79
95.44
99.54
103.01
98.60
95.74
93.92
94.98
100.33
101.86
Inventory Days
79.94
75.27
73.12
73.65
81.57
77.11
71.52
74.03
73.63
69.56
Payable days
84.78
96.23
108.56
108.07
99.98
100.14
39.56
39.46
37.10
31.00
Cash Conversion Cycle
98.95
74.48
64.10
68.59
80.19
72.70
125.88
129.55
136.86
140.42
Total Debt/Equity
0.20
0.14
0.07
0.06
0.18
0.17
0.14
0.28
0.41
0.40
Interest Cover
15.43
28.15
43.09
43.36
32.96
30.23
19.61
26.78
18.14
25.51

News Update:


  • Dr. Reddy's gets marketing authorization for generic semaglutide injection in Brazil
    5th Nov 2026, 12:10 PM

    The product will be available as a pre-filled, multi-dose injectable pen in two presentations, 2 mg/1.5 mL and 4 mg/3 mL

    Read More
  • Dr. Reddy's Laboratories secures USFDA’s tentative approval for injectable lenacapavir
    3rd Nov 2026, 14:11 PM

    The USFDA decision provides a regulatory basis for further steps, including WHO pre-qualification and national regulatory approvals

    Read More
  • Dr Reddy's Laboratories' Srikakulam unit gets USFDA’s VAI classification
    29th Oct 2026, 12:13 PM

    The USFDA had conducted PAI and GMP inspection at the company’s said unit in Andhra Pradesh

    Read More
  • Dr. Reddy’s Laboratories reports 31% fall in Q2 consolidated net profit
    26th Oct 2026, 10:39 AM

    Consolidated total income of the company declined by 3.26% to Rs 8,854.00 crore in Q2FY27

    Read More
  • Dr. Reddy's Labs. - Quarterly Results
    24th Oct 2026, 00:00 AM

    Read More
  • Dr. Reddy’s Laboratories gets nod for Zytorvi in advanced esophageal cancer
    21st Oct 2026, 12:59 PM

    The company entered into a licensing and commercialization agreement with Junshi Biosciences in 2023 for toripalimab across 21 countries

    Read More
  • USFDA completes pre-approval inspection at Dr. Reddy’s Visakhapatnam facility
    15th Oct 2026, 10:30 AM

    The company has been issued a Form 483 with three observations

    Read More
  • Dr. Reddy's Laboratories launches NIVORZ in India
    16th Sep 2026, 14:29 PM

    The launch of NIVORZ further strengthens the company's oncology portfolio and expands its presence in immuno-oncology

    Read More
  • USFDA completes GMP inspection at Dr. Reddy's manufacturing facility in Hyderabad
    17th Aug 2026, 12:59 PM

    The inspection was conducted from August 6, 2026 to August 14, 2026

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.